The global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018.The human immunodeficiency virus, or HIV, attacks the immune system by destroying the white blood cells (WBCs), called T-helper cells, or CD4 cells, making the body vulnerable to infections and other diseases. HIV drugs help prevent the multiplication of the virus and aid the immune system in resisting certain infections and other HIV-related complications, thereby providing a possibility of recovery to the patient.
Request for a free sample copy of this report: https://www.imarcgroup.com/hiv-drug-market/requestsample
Over the years, the rapid increase in diagnosis and treatment rates, along with easy access to healthcare facilities, have led to an increased demand for HIV drugs. Besides this, governments of various nations are taking initiatives and organizing education campaigns for community awareness regarding HIV diagnosis, prevention, treatment and care. Moreover, the manufacturers are launching innovative drugs with minimum or no side effects. They are also introducing generic drugs that offer the same treatment as branded drugs at a lower cost. This is anticipated to create a positive outlook for the global HIV drugs market in the upcoming years.
Explore full report with table of contents: https://www.imarcgroup.com/hiv-drug-market
- Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors – CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
- On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
- Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
- The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Browse Related Report
Contact US: IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: [email protected]
Follow us on twitter: @imarcglobal
Note: As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want to need latest primary and secondary data (2020-2025) with Cost Module, Business Strategy, Distribution Channel, etc. click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.